相关实验视频
Updated: Jan 16, 2026

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
13.0K
高度质瘤老年患者的并发症负担:对放射治疗结果的影响
Sophia M Leiss1, Benedikt Wiestler2,3, Helen X Hou4
1Department of Radiation Oncology, TUM School of Medicine and Health, TUM University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany. sophia.leiss@mri.tum.de.
BMC cancer
|October 2, 2025
概括
根据年龄调整的查尔森并发症指数 (ACCI) 对老年质母细胞瘤患者的预后价值有限. 糖尿病是预测该组整体存活率和无进展存活率的唯一一致的并发症.
科学领域:
- 神经瘤学神经瘤学
- 老年瘤学 老年瘤学
- 临床预后 临床预后
背景情况:
- 高度质瘤 (HGG) 或质母细胞瘤 (GBM) 的老年患者因年龄和并发症而面临独特的治疗挑战.
- 根据年龄调整的查尔森并发症指数 (ACCI) 用于预测生存率,但其在接受放射治疗 (RT) 或化疗放射治疗 (CRT) 的老年HGG患者的预后价值需要进一步调查.
研究的目的:
- 评估ACCI在老年HGG患者治疗RT或CRT的预后意义.
- 在这个患者群体中确定总生存 (OS) 和无进展生存 (PFS) 的关键预测因素.
主要方法:
- 在2001-2021年期间接受治疗的163名老年HGG患者 (≥60岁) 的回顾性分析.
- 卡普兰-梅尔分析通过ACCI组的中位数OS;多变量考克斯回归的OS和PFS.
- 随机生存森林 (RSF) 模型用于识别关键生存预测因素,包括ACCI,年龄,并发症和MGMT甲基化状态.
主要成果:
- 与较低ACCI (≤5) (22.6个月) 患者相比,较高ACCI (≥6) 的患者的平均寿命较短 (14.8个月).
- 糖尿病独立地预测了更糟糕的OS和PFS,与ACCI有显著的相互作用.
- 随机生存森林模型将年龄确定为主要的OS预测因子,MGMT甲基化作为主要的PFS预测因子,ACCI显示的贡献很小.
结论:
- 该ACCI表明,老年质母细胞瘤患者的预后价值有限且不一致.
- 糖尿病成为预测OS和PFS的唯一一致的并发症.
- 需要对更大的队列进行进一步的研究,以澄清ACCI在老年HGG患者治疗分层中的作用.
相关概念视频
Drug Dosing: Geriatric Patients
227
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
227
Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

